Live feed06:45:00·36dPRReleasevia QuantisnowMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 DevelopmentByQuantisnow·Wall Street's wire, on your screen.MRK· Merck & Company Inc.Health Care